Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mannan-conjugated birch pollen allergoid in birch pollen-induced allergic rhinitis/rhinoconjunctivitis
2024-515717-17-00Phase 3Completed
- Sponsor
- Inmunotek
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in birch pollen allergy and allergic rhinoconjunctivitis (ARC) comparing T502 mannan-conjugated birch pollen allergoid with Placebo (2 arms). Started Oct 2024; status: completed.
02
Drugs
mannan-conjugated betula pendula pollen allergoid vaccine
03
Conditions
birch pollen allergyallergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2024-515717-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515717-17-00.